Tecan Group AG (SWX:TECN)
Switzerland
· Delayed Price · Currency is CHF 126.00
-1.80 (-1.41%)
At close: Mar 9, 2026
Tecan Group AG Revenue
Tecan Group AG had revenue of 439.48M CHF in the half year ending June 30, 2025, a decrease of -18.84%. This brings the company's revenue in the last twelve months to 906.60M, down -9.34% year-over-year. In the year 2024, Tecan Group AG had annual revenue of 934.28M, down -13.04%.
Revenue (ttm)
906.60M
Revenue Growth
-9.34%
P/S Ratio
1.77
Revenue / Employee
302.20K
Employees
3,000
Market Cap
1.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 934.28M | -140.11M | -13.04% |
| Dec 31, 2023 | 1.07B | -69.88M | -6.11% |
| Dec 31, 2022 | 1.14B | 197.64M | 20.88% |
| Dec 31, 2021 | 946.62M | 215.74M | 29.52% |
| Dec 31, 2020 | 730.88M | 94.06M | 14.77% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 63.36B |
| Novartis AG | 44.94B |
| Galderma Group AG | 4.16B |
| Lonza Group AG | 6.53B |
| Medacta Group | 603.41M |
| Cosmo Pharmaceuticals | 170.24M |
| Aevis Victoria | 955.96M |
| SKAN Group AG | 332.13M |
Tecan Group AG News
- 5 months ago - Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook - GlobeNewsWire